Cidara Therapeutics Inc (CDTX) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.
Over the past 4 years, Cidara Therapeutics Inc has achieved a revenue compound annual growth rate (CAGR) of -53.0%.
Historical revenue and profitability trends for Cidara Therapeutics Inc
The chart above illustrates Cidara Therapeutics Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Cidara Therapeutics Inc's business.
How efficiently Cidara Therapeutics Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue Cidara Therapeutics Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Cidara Therapeutics Inc to continue growing earnings in the coming year. The consensus analyst rating is 4.4 based on 5 analysts.
Based on our comprehensive analysis, Cidara Therapeutics Inc (CDTX) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Cidara Therapeutics Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Cidara Therapeutics Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: CDTX Valuation, CDTX Dividend, CDTX Financial Health
Compare: CDTX vs AAPL, CDTX vs MSFT, CDTX vs GOOGL